To include your compound in the COVID-19 Resource Center, submit it here.

Amicus' SD-101 misses in Phase III for skin blistering disorder

Amicus Therapeutics Inc. (NASDAQ:FOLD) reported top-line data showing that SD-101 missed the two primary endpoints in the Phase III ESSENCE trial to treat simplex, recessive dystrophic or junctional non-Herlitz epidermolysis bullosa

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers